What is HC Wainwright’s Estimate for BHST FY2029 Earnings?

BioHarvest Sciences Inc. (NASDAQ:BHST) – Analysts at HC Wainwright reduced their FY2029 earnings estimates for BioHarvest Sciences in a research note issued to investors on Tuesday, April 14th. HC Wainwright analyst A. Dayal now expects that the company will earn $0.80 per share for the year, down from their prior estimate of $1.00. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share.

A number of other equities research analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Friday, March 27th. Roth Mkm began coverage on shares of BioHarvest Sciences in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, BioHarvest Sciences has a consensus rating of “Hold” and a consensus price target of $12.50.

BioHarvest Sciences Price Performance

Shares of NASDAQ:BHST opened at $4.30 on Wednesday. The company has a 50-day simple moving average of $4.44 and a 200-day simple moving average of $6.24. BioHarvest Sciences has a one year low of $4.10 and a one year high of $12.80. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.38 and a current ratio of 3.97. The stock has a market capitalization of $84.35 million, a price-to-earnings ratio of -7.05 and a beta of 1.16.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in BioHarvest Sciences during the fourth quarter worth about $60,000. XTX Topco Ltd purchased a new position in BioHarvest Sciences during the fourth quarter worth about $173,000. Quadrature Capital Ltd purchased a new position in BioHarvest Sciences during the fourth quarter worth about $140,000. Osaic Holdings Inc. raised its holdings in BioHarvest Sciences by 5,510.4% during the fourth quarter. Osaic Holdings Inc. now owns 35,233 shares of the company’s stock worth $183,000 after purchasing an additional 34,605 shares in the last quarter. Finally, Evercore Wealth Management LLC purchased a new position in BioHarvest Sciences during the fourth quarter worth about $724,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.